

Continuous positive airway pressure therapy withdrawal - a model to evaluate treatment modalities for sleep apnoea

Submission date	Recruitment status	<input type="checkbox"/> Prospectively registered
13/05/2009	No longer recruiting	<input type="checkbox"/> Protocol
Registration date	Overall study status	<input type="checkbox"/> Statistical analysis plan
14/07/2009	Completed	<input checked="" type="checkbox"/> Results
Last Edited	Condition category	<input type="checkbox"/> Individual participant data
02/02/2026	Nervous System Diseases	

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Malcolm Kohler

Contact details

Sleep Disorders Centre and Pulmonary Division
University Hospital of Zurich
Raemistrasse 100
Zurich
Switzerland
8091
+41 (0)44 255 97 51
Malcolm.K@bluewin.ch

Additional identifiers

Protocol serial number

V1.1

Study information

Scientific Title

Continuous positive airway pressure therapy withdrawal - a model to evaluate treatment modalities for sleep apnoea: a randomised controlled trial

Study objectives

Continuous positive airway pressure (CPAP) therapy withdrawal will result in gradual deterioration in daytime symptoms of obstructive sleep apnoea (OSA), sleep study parameters of OSA severity and an increase of blood pressure, endothelial dysfunction and systemic inflammation.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Local ethics committee of the University Hospital of Zurich approved on the 13th January 2009 (ref: EK-1600)

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Obstructive sleep apnoea

Interventions

Obstructive sleep apnoea patients under treatment with continuous positive airway pressure (CPAP) will be randomised to either continue with CPAP or to sham CPAP for 2 weeks. Total time of follow-up is 2 weeks.

Intervention Type

Other

Primary outcome(s)

Severity and symptoms of OSA, measured at least at baseline, after 1 week and after 2 weeks.

Key secondary outcome(s))

1. Blood pressure
2. Endothelial function
3. Systemic inflammation

Measured at least at baseline, after 1 week and after 2 weeks.

Completion date

31/12/2010

Eligibility

Key inclusion criteria

1. Objectively confirmed obstructive sleep apnoea with an original oxygen desaturation index (ODI) (greater than or equal to 4% dips) of between 10 and 50/h
2. Currently greater than 10 oxygen desaturations (greater than or equal to 4% dips) during an ambulatory nocturnal pulse oximetry performed at the end of a 4-night period without CPAP
3. Treated with CPAP for more than 12 months, minimal compliance 4 hours per night
4. Written informed consent
5. Aged 20 - 75 years (inclusive), either sex

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Total final enrolment

0

Key exclusion criteria

1. Previous ventilatory failure (awake resting arterial oxygen saturation less than 93% or arterial partial pressure of carbon dioxide [PCO₂] greater than 6 kPa)
2. Unstable, untreated coronary or peripheral artery disease, severe arterial hypertension (greater than 180/110 mmHg)
3. Previously diagnosed with Cheyne-Stokes breathing
4. Current professional driver
5. Any sleep related accident
6. Aged less than 20 or greater than 75 years at trial entry
7. Mental or physical disability precluding informed consent or compliance with the protocol
8. Non-feasible trial follow-up (for example, distance from follow-up centre, physical inability)

Date of first enrolment

01/07/2009

Date of final enrolment

31/12/2010

Locations

Countries of recruitment

Switzerland

Study participating centre

Sleep Disorders Centre and Pulmonary Division
Zurich
Switzerland
8091

Sponsor information

Organisation

University Hospital of Zurich (Switzerland)

ROR

<https://ror.org/01462r250>

Funder(s)

Funder type

Research organisation

Funder Name

Swiss National Science Foundation (Switzerland) (ref: 32003B_124915/1)

Alternative Name(s)

Schweizerischer Nationalfonds, Swiss National Science Foundation, Fonds National Suisse de la Recherche Scientifique, Fondo Nazionale Svizzero per la Ricerca Scientifica, Fonds National Suisse, Fondo Nazionale Svizzero, Schweizerische Nationalfonds, The Swiss National Science Foundation (SNSF), SNF, SNSF, FNS

Funding Body Type

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

Switzerland

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer-reviewed?	Patient-facing?
<u>Results article</u>	results	15/11/2011		Yes	No
<u>Other publications</u>	Relationship between hypoxic burden and cardiovascular effects in OSA - a post hoc analysis of an RCT	22/01/2026	02/02/2026	Yes	No